I recently had the pleasure to spend time with the team at Applied Clinical Trials. Following our discussion they published an interview in the September edition of Applied Clinical Trials Magazine. The interview is titled "Workforce Readiness Technology Minimizes Risk in Clinical Trials" and it explores how ArcheMedX is enabling Sponsors,
Ready, our operational intelligence and workforce readiness platform, received a very warm welcome from the clinical trials industry at the DIA 2019 Global Annual Meeting. During the Meeting, I was invited to join PharmaVoice to discuss how Ready analyzes behavioral data to enable Sponsors, CROs, and other trial stakeholders to evaluate
We know we should workout, but who doesn’t have an unused gym membership or a basement treadmill collecting dust. We know we should eat better, but who hasn’t stared at an empty container of Ben and Jerry’s while binge watching Game of Thrones. We all know we should get more sleep, but
The ArcheMedX team will be unveiling Ready and demonstrating the platform in the Innovators Hub (booth #2101) at the upcoming DIA Global Annual Meeting. Ready analyzes unique behavioral data to inform clinical operations. The result? Risks are identified sooner, resources are more effectively deployed, and staff and sites perform better.
I am thrilled to announce the launch of Ready, our new operational intelligence and workforce readiness platform for the clinical trials industry. This is an exciting time for the ArcheMedX team, and we would like to thank all those who have supported our growth and evolution. Ready enables clinical operations leaders to evaluate and improve
ArcheMedX to Reveal Ready, an Operational Intelligence and Workforce Readiness Platform, at DIA 2019 Global Annual Meeting
Charlottesville, VA, June 6, 2019 – ArcheMedX, the premier provider of operational intelligence and workforce readiness solutions for the life sciences and healthcare industries, is pleased to announce the launch of Ready, a new digital platform to reduce the risks and costs associated with underperforming clinical trials, at this year’s